Latest Funding News

West Wits Mining has released an updated Definitive Feasibility Study for its Qala Shallows project, revealing significant financial improvements and increased ore reserves. The study highlights a stronger gold price environment and refined mine plans that reduce capital requirements and accelerate payback.

Macarthur Minerals has updated its rights issue prospectus, introducing a cap on the underwriter's shareholding and revising key offer terms. These changes aim to balance funding needs with shareholder control and regulatory compliance.

Elsight Limited has raised A$60 million through a strongly supported placement, marking a milestone with consecutive record revenues and cash flow breakeven. The company is poised to capitalize on surging defence budgets and expanding drone markets with a robust pipeline of opportunities.

Sarama Resources has completed the acquisition of an 80% stake in the Mt Venn Gold Project, boosting its Laverton landholding to 1,000km² across two major projects. The move positions Sarama to explore promising gold and base metal targets in a prolific Australian gold district.

Austco Healthcare reports robust FY25 growth with revenue climbing over 37% and EBITDA soaring by more than 54%, fueled by strong organic performance and key acquisitions.

AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Paladin Energy reported a $18.4 million operating cash outflow in Q2 2025 but maintains a strong liquidity position with $89 million in cash and $139 million in total available funding.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.

QPM Energy has successfully raised $7 million through an oversubscribed Share Purchase Plan, significantly exceeding its initial $2 million target to accelerate key gas power projects in Queensland.

Astron Corporation has released updated economics for its Donald Rare Earth and Mineral Sands Project, showcasing robust financial metrics and targeting a Final Investment Decision by late 2025 with production slated for 2027.

Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.